Discuss on the Risk Control of Traditional Chinese Medicine

Chinese Journal of Pharmacovigilance ›› 2010, Vol. 7 ›› Issue (10): 607-610.

Previous Articles Next Articles

Discuss on the Risk Control of Traditional Chinese Medicine

WU Cheng-yun¹ ,HUANG Wen-zhi¹, ZHENG Qing-ming¹ ,ZHANG Li², ZHOU Ya-li¹ ,ZHANG Cheng-xu^2*

1.Sichuan Food and Drug Safety Monitoring and Evaluation Certification Center, Sichuan Chengdu 610017, China;
2.Center for Drug Reevaluation, SFDA, Beijing 100045, China

Received:2009-12-25 Revised:2016-03-12 Online:2010-10-08 Published:2016-03-09

Abstract

Abstract: This essay based on analyzing the pertinent literature, unscrambling the correlative laws and regulations of drug administration in force, and combining the situation of Traditional Chinese Medicine(TCM), The influential factors of TCM safety were discussed; as for the organizations relative to TCM, the responsibility and obligation were determined to controlling the risks from TCM, how and take what measures to decrease the risks were stated as well.

Key words: Traditional Chinese Medicine(TCM), risk control, adverse drug reaction(ADR)

CLC Number:

R954

WU Cheng-yun ,HUANG Wen-zhi, ZHENG Qing-ming ,ZHANG Li, ZHOU Ya-li ,ZHANG Cheng-xu . Discuss on the Risk Control of Traditional Chinese Medicine [J]. Chinese Journal of Pharmacovigilance, 2010, 7(10): 607-610.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2010/V7/I10/607

[1]	LI Min, LI Chunlei, SUN Cuicui, YU Wenwen, SUN Qing, QI Yingmei, LIU Anchang. One Case of Acute Generalized Exanthematous Pustulosis Caused by Abrocitinib Tablets [J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 823-825.
[2]	LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming. Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications” [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033.
[3]	JI Qiuxia, JIN Jian, ZHANG Bin. Pharmaceutical care for immune-related adverse events induced by toripalimab [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 346-348.
[4]	GUO Yijun, CHEN Xia, MENG Ping. Adverse drug reaction reports in 141 cases of orally administered targeted anti-tumor drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1137-1142.
[5]	HUO Yanfei, TIAN Yuejie, XU Lili, XIE Yanjun, CHANG Hong, SUN Chunxiao, LI Xia. 535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 921-926.
[6]	. Annual report of national adverse drug reaction monitoring (2022) [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 712-719.
[7]	ZHUANG Hongyan, ZANG Yannan, LIU Shanshan, NIU Mengxi, FANG Meng, YIN Dongqing, GUO Wei. Analysis of neuropsychiatric adverse reactions caused by zolpidem [J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 889-892.
[8]	ZHAO Yan, ZHAO Yifei^△, ZHENG Lijia, DONG Fang. Medical Device Vigilance Systems in European Union [J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 566-569.
[9]	SA Rina, ZHANG Bing, LIN Zhijian, WANG Xiaofang, ZHANG Xiaomeng. Pharmacovigilance of Traditional Chinese Medicine in Pharmaceutical Care in Medical Institutions [J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 422-426.
[10]	DENG Xia, LIU Bo, WANG Yuanzheng, YIN Xiao, SU Yao, ZHANG Yan, LI Yingli, GAO Chenyan, YANG Huan, WANG Tao. Antibody-Dependent Enhancement of Vaccines and Development of Coronavirus Vaccines [J]. Chinese Journal of Pharmacovigilance, 2021, 18(3): 201-205.
[11]	CHENG Jinlian, OUYANG Huitian, JIN Hongtao, ZHU Xueqi, XIAO Shuang, LEI Xiang, GAO Chunsheng, LIU Qingquan. Thoughts and Suggestions on Safety Evaluation of Combined use of Traditional Chinese Medicine in Clinical Research [J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 4-10.
[12]	PENG Shirong, CHEN Haiyan, WANG Qian, DING Qian, WANG Xiaoling. Risk Management of Pediatric Drug Clinical Trials [J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 564-566.
[13]	WENG Lihong, GAO Huan, HU Xue, ZHANG Wenrui. Infusion Requirements on Labels of 39 Chinese Traditional Medicine Injections [J]. Chinese Journal of Pharmacovigilance, 2020, 17(7): 437-440.
[14]	LYU Tianyi, KUANG Li, CHEN Mingying. Analysis of 1073 Cases of Clinical Use of Reduning Injection by Pareto Chart and Fishbone Diagram [J]. Chinese Journal of Pharmacovigilance, 2020, 17(10): 745-748.
[15]	XU Shungui. 105 Cases of Adverse Drug Reactions Indcued by Ibuprofen in Our Hosptial [J]. Chinese Journal of Pharmacovigilance, 2019, 16(3): 164-167.

Discuss on the Risk Control of Traditional Chinese Medicine

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics